Join the BioNap Email List!

Research Coverage

Some recent articles from BioNap, Inc.

Actinium Pharmaceuticals (ATNM)
Participation From Top BMT Centers A Good Sign >> LINK (April 2017)
EMA Gives Thumbs Up to SIERRA >> LINK (March 2017)
What's In Store for 2017 >> LINK (February 2017)
JPM Meeting Notes >> LINK (January 2017)
What Does Seattle Genetic's Clinical Hold Mean For Actinium >> LINK (January 2017)
ASH Abstract Confirms positive view for Actimab-A >> LINK (November 2016)
Comparing Actimab-A to Seattle Genetics CD33A >> LINK (October 2016)
Actinium Initiates Phase 3 with Iomab-B >> LINK (June 2016)
Odds of success look good with for Phase 2 Actimab-A >> LINK (June 2016)
How Celator's recent data in AML impacts Actinium >> LINK (March 2016)
Article looking at the CAR-T threat in AML >> LINK (Jan 2016)
Initiation Article (Introduction to ATNM) >> LINK (Nov 2015)

BioSig Technologies, Inc. (BSGM)
Journal Article Highlights Why PURE EP is Superior >> LINK (May 2017)
Secures Cash, Partners with Mayo >> LINK (March 2017)
BioSig's PURE EP, Explained >> LINK (February 2017)
Five Stocks That Should Get Acquired >> LINK (Sept 2016)
Mayo preclinical paper in JACC >> LINK (August 2016)
Partnership with Mayo Clinic >> LINK (July 2016)
Review of data at IDSS (BSGM vs. GE) >> LINK (May 2016)
Initiation Article (Introduction to BSGM)  >> LINK (March 2016)

BrainStorm Cell Therapeutics (BCLI)
Why Radical Approval is Good News For Brainstorm >> LINK (May 2017)
NurOwn Shows Potential In Autism >> LINK (April 2017)
Board, Management Expansions >> LINK (March 2017)
Time To Go Long Brainstorm? >> LINK (January 2017)
Interview with Chief of Neurology at MGH and ALS KOL >> LINK (November 2016)

BriaCell Therapeutics (BCTXF)
Phase 1/2a Trial Gets Underway >> LINK (May 2017)
Making the Investment Cash for BriaCell >> LINK (February 2017)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Poster with Biomarker analysis presented at AACR >> LINK (April 2016)
Article highlighting an impressive case study from Phase 1 trial >> LINK (Nov 2015)
Initiation Article (Introduction to BCT)  >> LINK (Oct 2015)

CanFite Biopharma (CANF)
Can-Fite Gearing Up For Phase 2 NASH Study >> LINK (March 2017)
Phase 3 RA Study Ready To Start >> LINK (February 2017)
CF101 Update In Psoriasis >> LINK (November 2016)
Article on CF102 for Phase 2 hepatocellular carcinoma >> LINK (July 2016)
Comprehensive update following Q4 Results >> LINK (Feb 2016)
Article comparing piclidenoson (CF101) to JAK inhibitors in RA >> LINK (Dec 2015)

CoLucid Pharmaceuticals (CLCD)
Why After A Massive Run, CoLucid Still Looks Attractive >> LINK (October 2016)
CoLucid Facts About Migraine >> LINK (May 2016)

Exactus, Inc. (EXDI)
An Introduction to FibriLyzer >> LINK (Sept 2016)

HedgePath Pharma (HPPI)
Why I'm Long HedgePath >> LINK (March 2017)
Update on Phase 2b Data Looks Excellent >> LINK (October 2016)
Analysis of Interim Phase 2b Data >> LINK (Aug 2016)
Introduction to HedgePath Pharma >> LINK (Aug 2016)

Immune Pharmaceuticals (IMNP)
Encouraging Phase 2 Data So Far in BP >> LINK (February 2017)
Immune forms Pain & Neurology spin-off called Maxim >> LINK (Sept. 2016)
Further elucidation on the strategy with Ceplene >> LINK (June 2016)
Ceplene biomarker data presented at AACR >> LINK (April 2016)
Article on Bertilimumab Phase 2 for Ulcerative Colitis >> LINK (Oct 2015)

MabVax Therapeutics (MBVX)
Posters at AACR on MVT-1075 >> LINK (April 2017)
FDA Clears MVT-1075 for Phase 1 >> LINK (February 2017)
Additional Phase 1 Data >> LINK (November 2016)
Five Stocks That Should Get Acquired >> LINK (Oct 2016)
Introduction to the Story >> LINK (Sept. 2016)

Matinas Biopharma (MTNB)
Well Positioned for June Data >> LINK (June 2017)
MAT2501 Phase 1 Data Looks Good >> LINK (March 2017)
A 5C Analysis of Matinas >> LINK (February 2017)
MAT2501 Phase 1 Trial Initiation >> LINK (December 2016)
Phase 2 VVC Study Initiation >> LINK (Nov. 2016)
Introduction to the story >> LINK (Nov. 2016)

Oryzon Genomics SA (ORY)
Update following Q4 Results >> LINK (March 2017)
Phase 1 ORY-1001 data at ASH >> LINK (December 2016)
Update following Q3 Results >> LINK (October 2016)
Update following Q2 Results >> LINK (August 2016)
Initiation Report (19-pages) >> LINK (Dec 2015)

Pieris Pharmaceuticals (PIRS)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Five Stocks That Should Get Acquired >> LINK (Sept 2016)
Target validation on PRS-060 >> LINK (June 2016)

RedHill Biopharma (RDHL)
R&D Day Highlights BEKINDA >> LINK (April 2017)
YELIVA gets Orphan Drug designation >> LINK (March 2017)
BEKINDA Phase 3 data expected in Q2 >> LINK (February 2017)
RHB-104 Final MS Data >> LINK (December 2016)
Update following Q3-2016 Results >> LINK (November 2016)
RHB-104 Phase just got more interesting >> LINK (October 2016)
Article on Mesupron (Phase 2 for solid tumors) >> LINK (Aug 2016)
Article on the RHB-104 (Phase 3 for Crohn's Disease) >> LINK (July 2016)
Phase 1 Data On YELIVA for Solid Tumors >> LINK (June 2016)
Interview with RDHL CEO, Dror Ben-Asher >> LINK (May 2016)
Article on RHB-105 (Phase 3 for H. pylori infection) Part-1 >> LINK (Feb 2016)

Relmada Therapeutics (RLMD)
What Cerecor's NMDA failure means for Relmada >> LINK (December 2016)
An Interview with Relmada Therapeutics >> LINK (October 2016)
Review of NMDA-receptor targeting for MDD >> LINK (July 2016)
Introduction to LevoCap-ER for pain >> LINK (June 2016)
Introduction to d-methadone for depression >> LINK (May 2016)

Revive Therapeutics (RVV.V)
Phase 2 Initiates, Revive Moves into Cannabis >> LINK (February 2017)
21st Century Cures Act a big positive for Revive >> LINK (December 2016)
Introduction to Bucillamine and Cystinuria >> LINK (June 2016)

Vaxil Bio Ltd (VXL.V)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Introduction to Vaxil and ImMucin neoantigen >> LINK (December 2016)

VistaGen Therapeutics (VTGN)
AV101 Potential in Neuropathic Pain >> LINK (May 2017)
Let's Talk Depression & NMDA >> LINK (March 2017)
Quick Thoughts >> LINK (February 2017)
Stem Cell deal with BlueRock >> LINK (December 2016)
What Cerecor's NMDA failure means for VistaGen >> LINK (December 2016)
Does AV101 Have Abilify-like Potential >> LINK (October 2016)
Five Stocks That Should Get Acquired >> LINK (October 2016)
Is VistaGen the Next Big Winner in CNS >> LINK (September 2016)
Interview with CMO Dr. Mark Smith >> LINK (Aug 2016)
Review of NMDA-receptor targeting for MDD >> LINK (July 2016)

No comments:

Post a Comment